AstraZeneca's gout drug lesinurad hit its primary endpoint in a Phase III trial, the company said, a welcome turn for one of the drugmaker's top prospects amid a thin slate of late-stage therapies.
The vaccine, which is designed to work through early inhibition of amyloid beta depositions, is due to enter Phase I trials next year.
ImmunoCellular Therapeutics put out the word Wednesday afternoon that its dendritic cell-based vaccine for brain cancer flunked the key overall survival test in Phase II, news that swiftly wiped out more than half of the small biotech's market cap as shares instantly cratered.
Duke University leads the way among schools with on-campus CROs, and now Oxygen Biotherapeutics has entrusted the institution with handling late-stage studies of its promising heart drug.
Avanir Pharmaceuticals watched its shares tank more than 20% after its lead pain candidate failed to outdo a placebo in a Phase II study of patients with multiple sclerosis.
After months of building investors' expectations for its Phase IIb study for the cancer conjugate aldoxorubicin as a potential first-line treatment for soft tissue sarcoma, the small-cap biotech CytRx today said that it found an 80% to 100% improvement in the progression-free survival rate for its new-and-improved chemotherapy drug compared to the original chemo, sending its shares up more than 70% in premarket trading.
The huge sales generated by Prevnar 13 mean Pfizer appears to have the pneumococcal vaccine sector sewn up, but Genocea Biosciences sees an opportunity to disrupt the monopoly. This week, the biotech began a Phase I clinical trial of the vaccine it thinks can unseat Prevnar.
AbbVie is rolling out its second snapshot of promising Phase III data for its hepatitis C cocktail, demonstrating that the vast majority of patients taking the therapy were cleared of the virus after 12 weeks of dosing.
The pharma giant is recruiting new patients while expanding the program with a new Phase III study for early-stage patients--without changing the dosing regimen.
Pfizer has joined the list of Big Pharmas caving to public pressure and opening up their data vaults, and that could mean a valuable trove of study results for CROs plotting new trials--assuming the drugmaker feels like sharing.